Gemcitabine trials for Pancreatic cancer

All Gemcitabine trials · All Pancreatic cancer trials

Phase breakdown

Recruiting trials studying Gemcitabine for Pancreatic cancer

• A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
  NCT07255404 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer
  NCT07049055 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
  NCT07283705 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
  NCT05859750 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 7 locations
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
  NCT04657068 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 164 locations
• A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
  NCT07024615 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 57 locations
• A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
  NCT05624918 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
  NCT07079228 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
  NCT07223047 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• AB122 Platform Study
  NCT04999761 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer
  NCT07619313 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
  NCT07444541 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
  NCT06219941 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 52 locations
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
  NCT07226856 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
  NCT06483555 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
  NCT04543071 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
  NCT03484299 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
  NCT05431270 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
  NCT05451043 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
  NCT03579836 · Phase: Phase 1, Phase 2 · Ages: 20 Years to 80 Years · Sex: All (male and female) · 1 location
• First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
  NCT06313970 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
  NCT06897644 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 28 locations
• Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
  NCT05841420 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer
  NCT03498326 · Phase: Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
  NCT06454383 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
  NCT06423326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
  NCT06576115 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
  NCT05827796 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
  NCT03257033 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 42 locations
• Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer
  NCT06491472 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06586515 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 104 locations
• ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
  NCT06904378 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients
  NCT06359275 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
  NCT03652428 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer
  NCT04894643 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
  NCT06951997 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07259317 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
  NCT04969731 · Phase: Phase 3 · Ages: 19 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
  NCT07575191 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
  NCT05482893 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 11 locations
• Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
  NCT05241249 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
  NCT05776524 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
  NCT05254171 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 93 locations
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
  NCT06445062 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 64 locations
• Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
  NCT06998940 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 274 locations
• Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
  NCT06958328 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 322 locations
• Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
  NCT06017284 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer
  NCT06196788 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Common questions

How many trials study Gemcitabine for Pancreatic cancer?

52 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.